Skip to main content
. 2022 Oct 17;45(12):2967–2975. doi: 10.2337/dc21-2688

Figure 2.

Figure 2

Persistence of islet graft function and HbA1c control by cohort. Red lines, islet-alone transplantation (IA) recipients; blue lines, islet-after-kidney transplantation (IAK) recipients. Time 0 for all panels was the day of first PHPI transplant. Fraction of subjects with continued PHPI graft function by C-peptide criterion at median and final follow-up: islet-alone, 0.84 and 0.56, respectively; islet-after-kidney, 0.69 and 0.49) (A). Fraction of subjects with continued HbA1c <7% (American Diabetes Association criterion) at median and final follow-up: islet-alone, 0.77 and 0.49; islet-after-kidney, 0.57 and 0.35) (B). Fraction of subjects with continued HbA1c ≤6.5% (American Association of Clinical Endocrinologists criterion) at median and final follow-up: islet-alone, 0.73 and 0.00; islet-after-kidney, 0.59 and 0.17) (C). D: Median HbA1c at baseline and modeled median HbA1c by years following initial PHPI transplant.